Evidence map›Paper›PMID 38056502›Full record

ArticleVirus research2024

Rapid increase in salivary IgA and broad recognition of spike protein following SARS-CoV-2 vaccination.

Kenji Ota, Hironori Sakai, Daisuke Sasaki, Fujiko Mitsumoto-Kaseida, Kei Sakamoto, Kosuke Kosai, Hiroo Hasegawa, Takahiro Takazono, Koichi Izumikawa, Hiroshi Mukae and 3 more

Abstract read
In one paragraph

Article in Virus research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kenji OtaDepartment of Laboratory Medicine, Nagasaki University Hospital, 1-7-1, Sakamoto, Nagasaki 852-8501, Japan. Electronic address: kenjiotamd@nagasaki-u.ac.jp.
Hironori SakaiCellSpect Co. Ltd., 2-4, Kita Iioka, Morioka, Iwate 020-0857, Japan.
Daisuke SasakiDepartment of Laboratory Medicine, Nagasaki University Hospital, 1-7-1, Sakamoto, Nagasaki 852-8501, Japan.
Fujiko Mitsumoto-KaseidaDepartment of Laboratory Medicine, Nagasaki University Hospital, 1-7-1, Sakamoto, Nagasaki 852-8501, Japan.
Kei SakamotoDepartment of Laboratory Medicine, Nagasaki University Hospital, 1-7-1, Sakamoto, Nagasaki 852-8501, Japan.
Kosuke KosaiDepartment of Laboratory Medicine, Nagasaki University Hospital, 1-7-1, Sakamoto, Nagasaki 852-8501, Japan.
Hiroo HasegawaDepartment of Laboratory Medicine, Nagasaki University Hospital, 1-7-1, Sakamoto, Nagasaki 852-8501, Japan.
Takahiro TakazonoDepartment of Respiratory Medicine, Nagasaki University Hospital, 1-7-1, Sakamoto, Nagasaki 852-8501, Japan.
Koichi IzumikawaInfection Control and Education Center, Nagasaki University Hospital, 1-7-1, Sakamoto, Nagasaki 852-8501, Japan.
Hiroshi MukaeDepartment of Respiratory Medicine, Nagasaki University Hospital, 1-7-1, Sakamoto, Nagasaki 852-8501, Japan.
Mya Myat Ngwe TunDepartment of Virology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, 1-12-4, Sakamoto, Nagasaki 852-8102, Japan.
Kouichi MoritaDepartment of Virology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, 1-12-4, Sakamoto, Nagasaki 852-8102, Japan; Dejima Infectious Disease Research Alliance, Nagasaki University, 1-12-4, Sakamoto, Nagasaki 852-8102, Japan.
Katsunori YanagiharaDepartment of Laboratory Medicine, Nagasaki University Hospital, 1-7-1, Sakamoto, Nagasaki 852-8501, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Saliva is a key component of mucosal immunity, which protects the oral cavity from viral infections. However, salivary immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in terms of immunoglobulin dynamics and recognition, have not been investigated sufficiently. In this study, saliva samples were collected from individuals that received SARS-CoV-2 vaccine, and immunoglobulin G (IgG), IgM, and IgA against whole spike protein and S1 protein were measured. IgA against whole spike protein increased significantly following vaccination, while IgA against S1 protein did not. Of note, the IgA response was evident two weeks after the first vaccine dose and continued to rise thereafter. On the contrary, IgG antibodies against S1 increased significantly at four weeks after vaccination. These results reveal the dynamics and recognition antigens of immunoglobulins in saliva, indicating the function of IgA in the mucosal immune system. These findings may pave the way for further studies on mucosal immune response induced by vaccination.

Indexed as

COVID-19COVID-19 VaccinesAntibodies, ViralHumansImmunoglobulin AImmunoglobulin GSARS-CoV-2Spike Glycoprotein, CoronavirusVaccinationAntibodies, ViralCOVID-19 VaccinesImmunoglobulin AImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2IgAIgGMucosal immunitySalivaSARS-CoV-2Vaccine

Identifiers

PMID38056502
PMCPMC10749273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.